CorMedix

Yahoo Finance • last month

CorMedix outlines $300M–$320M revenue and $100M–$125M EBITDA targets for 2026 amid DefenCath transition and Melinta integration

Earnings Call Insights: CorMedix Inc. (CRMD) Q4 2025 MANAGEMENT VIEW * CEO Joseph Todisco stated that “2025 was truly a transformational year for CorMedix. While DefenCath achieved peak sales of just under $260 million, we are excited... Full story

Yahoo Finance • 2 months ago

Lowest Quant ranked small-cap stocks with positive EPS surprises

[Wall street sign on manhattan] franckreporter/iStock via Getty Images With the Q4 earnings season almost coming to an end, below is a list of small-cap stocks with positive quarterly EPS surprises ranked according to their lowest Seeking... Full story

Yahoo Finance • 2 months ago

Catalyst Watch: Crypto swings, FedEx investor event, and Super Bowl bets

[Stock exchange building columns stock market finance] alexsl Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next we... Full story

Yahoo Finance • 5 months ago

Buy Rating Reaffirmed: CorMedix Inc. (CRMD) Posts Profitability and Expands Outlook for 2025

CorMedix Inc. (NASDAQ:CRMD) is one of the best breakout stocks to invest in. On November 13, H.C. Wainwright’s Brandon Folkes reaffirmed a Buy on CorMedix Inc. (NASDAQ:CRMD), citing strong DefenCath-driven revenue, Melinta acquisition syne... Full story

Yahoo Finance • 5 months ago

H.C. Wainwright Raises the PT on ​CorMedix Inc. (CRMD), Keeps a Buy

​CorMedix Inc. (NASDAQ:CRMD) is one of the Fast-Growing Small Cap Stocks to Buy According to Analysts. On November 13, H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating on CorMedix Inc. (NASDAQ:CRMD) and raised the price targe... Full story

Yahoo Finance • 5 months ago

CorMedix raises 2025 revenue guidance to $390M-$410M amid accelerated Melinta integration and DefenCath momentum

Earnings Call Insights: CorMedix Inc. (CRMD) Q3 2025 MANAGEMENT VIEW * CEO Joseph Todisco highlighted the completion and rapid integration of the Melinta Therapeutics acquisition, describing it as "transformational for CorMedix creatin... Full story

Yahoo Finance • 5 months ago

Strong Earnings and Biotech Resilience Define the Midweek Momentum

DENVER, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kraig Labs (OTCQB: KBLB) Spins the Future — Decades of Failure Give Way to a Commercial Breakthrough After decades of failed attempts by corporate giants and research consortia across the globe... Full story

Yahoo Finance • 5 months ago

CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance

‒ Q3 2025 Net Revenue of $104.3 million; Pro Forma Net Revenue of $130.8 million ‒ ‒ Q3 2025 Net Income of $108.6 million; Adjusted EBITDA of $71.9 million ‒ ‒ FY 2025 Pro Forma Net Revenue Guidance Raised to a Range of $390 to $410 mill... Full story

Yahoo Finance • 6 months ago

CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance

‒ Q3 2025 Unaudited Pro Forma Net Revenue of more than $125 million ‒ ‒ Q3 2025 Unaudited DefenCath Net Revenue of more than $85 million ‒ ‒ Raising FY 2025 Pro Forma Net Revenue Guidance to at least $375 million ‒ ‒ ~$30mm of operating... Full story

Yahoo Finance • 6 months ago

13 Top Stocks With Huge Upside Potential To Buy Now

Buying stocks when the market is setting all-time highs can be a bit nerve-wracking. On the one hand, markets often continue to make new highs once they break through to new records. Conversely, nothing goes up in a straight line. After ba... Full story

Yahoo Finance • 6 months ago

CorMedix files to sell 6.32M shares of common stock for holders

* CorMedix (NASDAQ:CRMD [https://seekingalpha.com/symbol/CRMD]) has filed to sell 6,323,833 shares of common stock for holders. * Filing [https://seekingalpha.com/filing/10505274] MORE ON * Crocs: Don't Be Fooled By The Low P/E [ht... Full story

Yahoo Finance • 6 months ago

CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO

- Enrollment Completed in Ongoing Phase III ReSPECT Study in Prophylaxis of Fungal Infections in Adult Patients Undergoing Allogeneic Blood and Marrow Transplant - - Topline Results from ReSPECT Study Expected in 2Q 2026 - BERKELEY HEIGH... Full story

Yahoo Finance • 7 months ago

Talphera announces private placement financing of up to $29M priced at-the market

* Talphera (NASDAQ:TLPH [https://seekingalpha.com/symbol/TLPH]) on Monday said it has entered into securities purchase agreements with CorMedix (NASDAQ:CRMD [https://seekingalpha.com/symbol/CRMD]) and certain institutional investors for... Full story

Yahoo Finance • 7 months ago

CorMedix Inc (NASDAQ:CRMD) Embodies a Proven Growth Investing Strategy

In the world of growth investing, few strategies have kept their importance as well as the principles found in Louis Navellier’s “The Little Book That Makes You Rich.” The method focuses on finding companies showing strong, speeding growth... Full story

Yahoo Finance • 7 months ago

CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team

- Transformational deal for CorMedix that expands and diversifies company’s commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential - - Revised guidance... Full story

Yahoo Finance • 8 months ago

CorMedix to Participate in Upcoming Investor Conferences

BERKELEY HEIGHTS, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions,... Full story

Yahoo Finance • 8 months ago

Elliott Management takes new stake in Hewlett Packard, exits Arm, among Q2 moves

[The New York Times 2014 DealBook Conference] Thos Robinson Elliott Management, the hedge fund run by billionaire investor Paul Singer, took new stakes in Hewlett Packard Enterprise Company (NYSE:HPE [https://seekingalpha.com/symbol/HPE])... Full story

Yahoo Finance • 8 months ago

Needham Maintains a Buy Rating on CorMedix (CRMD) With a $20 PT

CorMedix Inc. (NASDAQ:CRMD) is one of the top most undervalued biotech stocks to buy now. On August 7, Needham analyst Serge Belanger maintained a Buy rating on CorMedix Inc. (NASDAQ:CRMD) and set a price target of $20.00.Is CorMedix Inc.... Full story

Yahoo Finance • 9 months ago

Important Notice to Long-Term Shareholders of CorMedix Inc. (NASDAQ: CRMD); Maison Solutions, Inc. (NASDAQ: MSS); Napco Security Technologies, Inc. (NASDAQ: NSSC); and Treace Medical Concepts, Inc. (NASDAQ: TMCI); Grabar Law Office is Investigating Claims on Your Behalf as Key Developments Occur in Underlying Class Actions

PHILADELPHIA, July 09, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD) Shareholder Class Action Survives Motion to Dismiss: Current CorMedix Inc. (NASDAQ: CRMD) shareholders who have held CorMedix shares since prior to October 16... Full story

Yahoo Finance • 9 months ago

Important Notice to Long-Term Shareholders of AdaptHealth Corp. (NASDAQ: AHCO); CorMedix Inc. (NASDAQ: CRMD); Napco Security Technologies, Inc. (NASDAQ: NSSC); and Virtu Financial Inc. (NYSE: VIRT): Grabar Law Office is Investigating Claims on Your Behalf as Key Developments Occur in Underlying Class Actions

PHILADELPHIA, July 02, 2025 (GLOBE NEWSWIRE) -- AdaptHealth Corp. (NASDAQ: AHCO) Shareholder Class Action Stayed Pending Mediation: A federal securities fraud class action alleging that AdaptHealth Corp. (NASDAQ: AHCO), and certain of i... Full story